Abstract

http://ssrn.com/abstract=889326
 
 

Footnotes (156)



 


 



The Generic Biologics Debate: Industry's Unintended Admission that Biotech Patents Fail Enablement


Gregory N. Mandel


Temple University - James E. Beasley School of Law


Virginia Journal of Law and Technology, Vol. 11, No. 8, 2006

Abstract:     
This Article reveals that many already issued and actively enforced medical biotechnology patents may be invalid. Biologics, medical therapeutics derived through biotechnology techniques, are the fastest growing and most promising pharmaceutical sector. They represent a $45 billion a year industry that is anticipated to double in five years and that already provides novel treatments for cancer, diabetes, and heart disease. Due to unforeseen consequences of past decisions, manufacturers currently are significantly limited in their ability to sell generic copies of biologics even after the pioneer biologic patents expire. As early biologics are starting to go off-patent, this regulatory mix-up is having a notable impact on the availability of biologics and raising the cost of health care.

The generic biologics debate has dramatically heated-up recently due to proposed legislation to create a new regulatory process for generic biologics, the biotechnology and pharmaceutical industry defending the status quo, and the Food and Drug Administration struggling to handle the situation. This Article exposes for the first time that industry's own arguments have an unintended, striking consequence — many of their biologic patents fail enablement, and therefore are not valid in the first instance.

Number of Pages in PDF File: 25

Keywords: biologic, biotechnology, biotech, biopharmaceutical, generic, FDA, drug, patent, enablement

JEL Classification: I10, I18, K23, K32

working papers series


Download This Paper

Date posted: March 21, 2006  

Suggested Citation

Mandel, Gregory N., The Generic Biologics Debate: Industry's Unintended Admission that Biotech Patents Fail Enablement. Virginia Journal of Law and Technology, Vol. 11, No. 8, 2006. Available at SSRN: http://ssrn.com/abstract=889326 or http://dx.doi.org/10.2139/ssrn.889326

Contact Information

Gregory Mandel (Contact Author)
Temple University - James E. Beasley School of Law ( email )
1719 N. Broad Street
Philadelphia, PA 19122
United States
(215) 204-2381 (Phone)
Feedback to SSRN


Paper statistics
Abstract Views: 2,592
Downloads: 682
Download Rank: 20,002
Footnotes:  156

© 2014 Social Science Electronic Publishing, Inc. All Rights Reserved.  FAQ   Terms of Use   Privacy Policy   Copyright   Contact Us
This page was processed by apollo8 in 0.281 seconds